v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2024   2,023,351        
Beginning balance at Dec. 31, 2024 $ 3,188,844 $ 20,234 $ 64,284,462 $ 181,148 $ (61,458,439) $ 161,439
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock in relation to vested restricted stock units and grants (in shares)   56,042        
Issuance of common stock in relation to vested restricted stock units and grants (14,880) $ 560 (15,440)      
Issuance of common stock, prefunded warrants, and common stock warrants, net of fees (in shares)   414,202        
Issuance of common stock, prefunded warrants, and common stock warrants, net of fees 3,210,023 $ 4,142 3,205,881      
Reverse stock split rounding (in shares)   1,695        
Reverse stock split rounding 0 $ 17 (17)      
Stock-based compensation 268,339   268,339      
Currency translation adjustment (175,784)     (175,784)    
Net Loss (3,869,345)       (3,869,345)  
Ending balance (in shares) at Jun. 30, 2025   2,495,290        
Ending balance at Jun. 30, 2025 2,607,197 $ 24,953 67,743,225 5,364 (65,327,784) 161,439
Beginning balance (in shares) at Mar. 31, 2025   2,487,052        
Beginning balance at Mar. 31, 2025 4,244,618 $ 24,871 67,535,255 138,879 (63,615,826) 161,439
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock in relation to vested restricted stock units and grants (in shares)   8,238        
Issuance of common stock in relation to vested restricted stock units and grants 269 $ 82 187      
Stock-based compensation 207,783   207,783      
Currency translation adjustment (133,515)     (133,515)    
Net Loss (1,711,958)       (1,711,958)  
Ending balance (in shares) at Jun. 30, 2025   2,495,290        
Ending balance at Jun. 30, 2025 2,607,197 $ 24,953 67,743,225 5,364 (65,327,784) 161,439
Beginning balance (in shares) at Dec. 31, 2025   5,245,631        
Beginning balance at Dec. 31, 2025 8,888,307 $ 52,456 78,446,696 11,254 (69,783,538) 161,439
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock in relation to vested restricted stock units and grants (in shares)   314,906        
Issuance of common stock in relation to vested restricted stock units and grants (183,712) $ 3,149 (186,861)      
Issuance of shares of common stock in connection with acquisition of Lexverify Ltd. (in shares)   78,754        
Issuance of shares of common stock in connection with acquisition of Lexverify Ltd. 400,000 $ 788 399,212      
Stock-based compensation 566,309   566,309      
Currency translation adjustment 53,432     53,432    
Net Loss (4,925,245)       (4,925,245)  
Ending balance (in shares) at Jun. 30, 2026   5,639,291        
Ending balance at Jun. 30, 2026 4,799,091 $ 56,393 79,225,356 64,686 (74,708,783) 161,439
Beginning balance (in shares) at Mar. 31, 2026   5,285,008        
Beginning balance at Mar. 31, 2026 7,341,078 $ 52,850 79,106,413 35,310 (72,014,934) 161,439
Increase (Decrease) in Stockholders' Equity            
Issuance of common stock in relation to vested restricted stock units and grants (in shares)   314,906        
Issuance of common stock in relation to vested restricted stock units and grants (183,712) $ 3,149 (186,861)      
Issuance of shares of common stock in connection with acquisition of Lexverify Ltd. (in shares)   39,377        
Issuance of shares of common stock in connection with acquisition of Lexverify Ltd. 0 $ 394 (394)      
Stock-based compensation 306,198   306,198      
Currency translation adjustment 29,376     29,376    
Net Loss (2,693,849)       (2,693,849)  
Ending balance (in shares) at Jun. 30, 2026   5,639,291        
Ending balance at Jun. 30, 2026 $ 4,799,091 $ 56,393 $ 79,225,356 $ 64,686 $ (74,708,783) $ 161,439